However, IVIg induces clinical improvement in OMS [1], and APRIL is not elevated in untreated OMS, raising the possibility that boosting serum APRIL could be therapeutic in OMS. The gene discussed is TNFSF13; the disease is opsoclonus-myoclonus syndrome.